Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness

Thrombosis and Haemostasis

Volumn 102, Issue 4, 2009, Pages 772-778

  Armstrong, Paul C J ^a   Dhanji, Al Rehan ^a   Truss, Nicola J ^a   Zain, Zetty N M ^a   Tucker, Arthur T ^a,b   Mitchell, Jane A ^c   Warner, Timothy D ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Aggregation; Aspirin; Clopidogrel; Platelets

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLSALICYLIC ACID; ADRENALIN; ARACHIDONIC ACID; CLOPIDOGREL; COLLAGEN; RISTOCETIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE 6;

ADULT; AREA UNDER THE CURVE; ARTICLE; CELL ADHESION; CLINICAL EXAMINATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HUMAN EXPERIMENT; MALE; MEASUREMENT; NORMAL HUMAN; PLATE AGGREGOMETRY; PRIORITY JOURNAL; SEROLOGY; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION;

ASPIRIN; BLOOD PLATELETS; CELLS, CULTURED; DRUG COMBINATIONS; FEASIBILITY STUDIES; HUMANS; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; THROMBOSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 70449496136     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-04-0215     Document Type: Article

References (42)

1. Cattaneo M. Laboratory detection of 'aspirin resistance': what test should we use (if any)? Eur Heart J 2007; 28: 1673-1675.
2. Lordkipanidze M, Pharand C, Schampaert E, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28: 1702-1708. (Pubitemid 47227104)
3. Serebruany VL, Goto S. The challenge of monitoring platelet response after clopidogrel. Eur Heart J 2008; 29: 2833-2834.
4. Smith SC, Jr., Feldman TE, Hirshfeld JW, Jr., et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention - Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: 156-175.
5. Gurbel PA, Becker RC, Mann KG, et al. Platelet Function Monitoring in Patients With Coronary Artery Disease. Journal of the American College of Cardiology 2007; 50: 1822-1834. (Pubitemid 350007957)
6. Cairns JA, Eikelboom J. The Pursuit of Clinically Relevant Measures of Platelet Function After Antiplatelet Drug Therapy. J Am Coll Cardiol 2008; 52: 1978-1980.
7. Wang ZJ, Zhou YJ, Liu YY, et al. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent. Thrombosis Research 2009; 124: 46-51.
8. Fratantoni JC, Poindexter BJ. Measuring platelet aggregation with microplate reader. A new technical approach to platelet aggregation studies. Am J Clin Pathol 1990; 94: 613-617.
9. Bednar B, Condra C, Gould RJ, et al. Platelet aggregation monitored in a 96 well microplate reader is useful for evaluation of platelet agonists and antagonists. Thrombosis Research 1995; 77: 453-463.
10. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
11. Mehta SR, Yusuf S, Peters RJG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. The Lancet 2001; 358: 527-533. (Pubitemid 32772726)
12. Saw J, Madsen EH, Chan S, et al. The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) Study. J Am Coll Cardiol 2008; 52: 1826-1833.
13. Sacco RL, Diener H-C, Yusuf S, et al. Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke. N Engl J Med 2008; 359: 1238-1251.
14. Gori AM, Marcucci R, Migliorini A, et al. Incidence and Clinical Impact of Dual Nonresponsiveness to Aspirin and Clopidogrel in Patients With Drug-Eluting Stents. Journal of the American College of Cardiology 2008; 52: 734-739.
15. Bowry ADK, Brookhart MA, Choudhry NK. Meta- Analysis of the Efficacy and Safety of Clopidogrel Plus Aspirin as Compared to Antiplatelet Monotherapy for the Prevention of Vascular Events. The American Journal of Cardiology 2008; 101: 960-966.
16. De Miguel A, Ibanez B, Badimon JJ. Clinical implications of clopidogrel resistance. Thromb Haemost 2008; 100: 196-203.
17. Hankey GJ, Eikelboom JW. Aspirin resistance. The Lancet 2006; 367: 606-617.
18. Hanjis C, Frishman WH, Lerner RG. Aspirin resistance: mechanisms and clinical implications. Cardiol Rev 2006; 14: 18-25. (Pubitemid 44378520)
19. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and Clopidogrel Drug Response in Patients Undergoing Percutaneous Coronary Intervention: The Role of Dual Drug Resistance. Journal of the American College of Cardiology 2006; 47: 27-33. (Pubitemid 43005160)
20. Rocca B, Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. Journal of Thrombosis and Haemostasis 2005; 3: 1597-1602. (Pubitemid 41716544)
21. Zimmermann N, Hohlfeld T. Clinical implications of aspirin resistance. Thromb Haemost 2008; 100: 379-390.
22. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992-1000. (Pubitemid 351844676)
23. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted Clopidogrel Loading Doses According to Vasodilator- Stimulated Phosphoprotein Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance: A Multicenter Randomized Prospective Study. Journal of the American College of Cardiology 2008; 51: 1404-1411.
24. Michelson AD. Platelet Function Testing in Cardiovascular Diseases. Circulation 2004; 110: e489-493.
25. Jennings I, Woods TAL, Kitchen S, et al. Platelet function testing: practice among UK National External Quality Assessment Scheme for Blood Coagulation participants, 2006. J Clin Pathol 2008; 61: 950-954.
26. Cattaneo M, Hayward CP, Moffat KA, et al. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost 2009; 7: 1029.
27. Harrison P, Frelinger AL, 3rd, Furman MI, et al. Measuring antiplatelet drug effects in the laboratory. Thromb Res 2007; 120: 323-336.
28. Rand ML, Leung R, Packham MA. Platelet function assays. Transfus Apheresis Sci 2003; 28: 307-317.
29. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115: 3156-3164. (Pubitemid 47012230)
30. Macchi L, Christiaens L, Brabant S, et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thrombosis Research 2002; 107: 45-49. (Pubitemid 35284424)
31. Gremmel T, Steiner S, Seidinger D, et al. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 2009; 101: 333-339.
32. Lordkipanidze M, Pharand C, Nguyen TA, et al. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 2008; 29: 2877-2885.
33. Angiolillo DJ, Alfonso F. Platelet function testing and cardiovascular outcomes: steps forward in identifying the best predictive measure. Thromb Haemost 2007; 98: 707-709. (Pubitemid 47555058)
34. Armstrong PC, Truss NJ, Ali FY, et al. Aspirin and the in vitro linear relationship between thromboxane A(2) mediated platelet aggregation and platelet production of thromboxane A(2). J Thromb Haemost 2008; 6: 1933-1943.
35. Bellavite P, Andrioli G, Guzzo P, et al. A colorimetric method for the measurement of platelet adhesion in microtiter plates. AnalBiochem 1994; 216: 444-450. (Pubitemid 24076032)
36. Gasparyan AY, Watson T, Lip GYH. The Role of Aspirin in Cardiovascular Prevention: Implications of Aspirin Resistance. Journal of the American College of Cardiology 2008; 51: 1829-1843. (Pubitemid 351615246)
37. Shantsila E, Lip GY. 'Aspirin resistance' or treatment non-compliance: which is to blame for cardiovascular complications? J Transl Med 2008; 6: 47.
38. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003; 110: 255-258.
39. Angiolillo DJ, Guzman LA, Bass TA. Current antiplatelet therapies: Benefits and limitations. American Heart Journal 2008; 156: 3S-9S.
40. Kattlove HE, Gomez MH. Studies on the mechanism of ristocetin-induced platelet aggregation. Blood 1975; 45: 91-96.
41. Ali FY, Warner TD, Mitchell JA. Comparison of responses in IP and PPARb deleted murine platelets. Heart Online 2008; 94: e22.
42. Ali FY, Armstrong PC, Dhanji AR, et al. Antiplatelet actions of statins and fibrates are mediated by PPARs. Arterioscler Thromb Vasc Biol 2009; 29: 706-711.